European Urology

Bladder and Urothelial Cancer

Evaluation of the BTA Tests for the Detection of Bilharzial Related Bladder Cancer: The Cairo Experience

Khaled H.M.a · Khaled H.M.a · Abdel-Salam I.a · Abdel-Salam I.a · Abdel-Gawad M.a · Abdel-Gawad M.a · Metwally A.a · Metwally A.a · El-Demerdash S.a · El-Demerdash S.a · El-Didi M.a · El-Didi M.a · Morsi A.a · Morsi A.a · Ishak L.b · Ishak L.b

Author affiliations

aCairo National Cancer Institute, Cairo, Egypt; bBion Diagnostic Sciences, Redmond, Wash., USA

Keywords: Bladder cancerBladder neoplasmsBTA stat testBTA TRAK testBilharziasis

Related Articles for ""
Eur Urol 2001;39:91–94
https://doi.org/10.1159/000052418

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact Karger service

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Bladder and Urothelial Cancer

Published online: December 22, 2000
Issue release date: January 2001

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 3

ISSN: 0302-2838 (Print)
eISSN: 1873-7560 (Online)

For additional information: https://www.karger.com/EUR

Abstract

Objective: To evaluate the clinical performance of the BTA stat test and the BTA TRAK assay in the diagnosis of bilharzia–related bladder cancer and to calculate a new ‘Egyptian’ cut–off value for the BTA TRAK (quantitative) assay. Methods: Urine samples of 149 individuals were tested for the presence of the human complement factor H–related protein, the antigen detected by the BTA stat and BTA TRAK tests. The group consisted of 53 healthy volunteers, 20 patients with active bilharziasis, 11 patients with other urologic disorders including prostate cancer, and 65 patients with histologically proven bladder cancer. All samples were obtained prior to surgery or therapy. Results: The BTA stat test was positive in 64 of 65 samples from patients with bladder cancer, for an overall sensitivity of 99%. With a BTA TRAK assay cut–off of 60 U/ml (set at 97% specificity in the healthy population), the sensitivity of the TRAK assay was 94%. There was no statistically significant difference between the sensitivities of the two BTA tests in patients diagnosed with squamous cell carcinoma and those with transitional cell carcinoma. The overall specificity of the BTA stat test was 67% ranging from 15% in patients with bilharziasis to 94% in healthy volunteers. The overall specificity of the TRAK assay was 66%, again with negative results in 15% of the patients with bilharziasis. Conclusions: The BTA stat test and TRAK tests are extremely sensitive in the detection of bladder cancer in the Egyptian population. Positive results (85%) are also observed in patients with active bilharziasis, which often leads to bladder cancer. Longitudinal follow–up of these positive cases is needed to determine whether these positive results are false or predictive of bladder cancer.



Related Articles:

References

  1. Sherif M, Ibrahim AS: The incidence of cancer in Egypt; in Sherif M, Ibrahim AS (eds): The Profile of Cancer in Egypt (CRMCA). Cairo, Arab World Printing House, 1987, pp 179–183.
  2. El–Bolkainy MN, Mokhtar NM, Ghoneim MA, Hussein MH: The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer 1991;48:2643–2648.
  3. El–Bolkainy MN: Bladder cancer and bilharziasis in Egypt; in Grundmann (ed): Cancer Campaign, vol 6: Cancer Epidemiology. New York, 1982, pp 41–79.
  4. Koraitium M, Metwali N, Atta M, Karam M, El–Sadr A: Schistosomal bladder carcinoma: Is it changing? J Egypt Natl Cancer Inst 1991;5 (2):309–314.
  5. Leyh H, Marberger M, Conort P, Sternberg C, Pansadoro V, Pagano F, Bassi P, Boccon–Gibod L, Raven V, Treiber U, Ishak L: Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol 1999; 35:52–56.
    External Resources
  6. Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I: Noninvasive detection of bladder cancer with the BTA stat test. J Urol 1999;161: 443–446.
    External Resources
  7. Kinders R, Jones T, Root R, Bruce C, Murchison H, Corey M, Williams L, Enfield D, Hass GM: Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 1998;4:2511–2520.
    External Resources
  8. Ellis W, Blumenstein B, Ishak L, Enfield D: Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. Urology 1997;50:882–887.
    External Resources
  9. Heicappell R, Wettig I, Schostak M, Muller M, Steiner U, Sauter T, Miller K: Quantitative detection of human complement factor H–related protein in transitional cell carcinoma of the urinary bladder. Eur Urol 1999;35:81–87.
    External Resources
  10. Thomas L, Leyh H, Marberger M, Bombardieri E, Bassi P, Pagano F, Pansadoro V, Sternberg CN, Boccon–Gibod L, Ravery V, Le Guludec D, Meulemans A, Conort P, Ishak L: Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem 1999;45(4):472–477.
  11. Hermanek P, Sobin LH: UICC – International Union against Cancer TNM Classification of Malignant Tumours, ed 4. Heidelberg, Springer, 1987.

Article / Publication Details

First-Page Preview
Abstract of Bladder and Urothelial Cancer

Published online: December 22, 2000
Issue release date: January 2001

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 3

ISSN: 0302-2838 (Print)
eISSN: 1873-7560 (Online)

For additional information: https://www.karger.com/EUR

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2001, Vol.39, No. 1

January 2001

Article

Recommend This
TOP